<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Impaired effectiveness of <z:chebi fb="105" ids="17234">glucose</z:chebi> to suppress endogenous <z:chebi fb="105" ids="17234">glucose</z:chebi> production (EGP) is an important cause of worsening <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Elevated free fatty acids (FFAs) may impair <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness via several mechanisms, including rapid changes in metabolic fluxes and/or more gradual changes in gene expression of key enzymes or other proteins </plain></SENT>
<SENT sid="2" pm="."><plain>Thus, we examined the magnitude and time course of effects of FFAs on <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and whether <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness can be restored by lowering FFAs </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> fluxes ([3-(3)H]-<z:chebi fb="105" ids="17234">glucose</z:chebi>) were measured during 6-h pancreatic clamp studies, at euglycemia (5 mmol/l <z:chebi fb="105" ids="17234">glucose</z:chebi>, t=0-240 min), and <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> (10 mmol/l, t=240-360 min) </plain></SENT>
<SENT sid="4" pm="."><plain>We studied 19 poorly controlled subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (HbA(1c) 10.9 +/- 0.4%, age 50 +/- 3 years, BMI 30 +/- 2 kg/m(2)) on at least two occasions with saline (NA- group) or <z:chebi fb="5" ids="15940">nicotinic acid</z:chebi> (NA group) infusions for 3, 6, or 16 h (NA3h, NA6h, and NA16h groups, respectively) to lower FFAs to nondiabetic levels </plain></SENT>
<SENT sid="5" pm="."><plain>As a reference group, <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness was also assessed in 15 nondiabetic subjects </plain></SENT>
<SENT sid="6" pm="."><plain>There was rapid improvement in hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness following only 3 h of NA infusion (NA3h = 31 +/- 6% suppression of EGP with <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> vs. NA- = 8 +/- 7%; P&lt;0.01) and complete restoration of <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness after 6 h of NA (NA6h = 41 +/- 8% suppression of EGP; P = NS vs. nondiabetic subjects) </plain></SENT>
<SENT sid="7" pm="."><plain>Importantly, the loss of hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is completely reversible upon correcting the increased FFA concentrations </plain></SENT>
<SENT sid="8" pm="."><plain>A longer duration of FFA lowering may be required to overcome the <z:hpo ids='HP_0011010'>chronic</z:hpo> effects of increased FFAs on hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness </plain></SENT>
</text></document>